HOMA-IR

What is HOMA-IR?

Insulin resistance is one of the most clinically significant metabolic abnormalities in modern medicine — and one of the most underdiagnosed. It sits at the root of type 2 diabetes, metabolic syndrome, polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease, and cardiovascular disease. Yet for most of its course, it produces no obvious symptoms. Blood sugar can remain seemingly normal for years while insulin resistance quietly worsens in the background — because the pancreas compensates by producing more and more insulin to overcome the resistance. By the time blood sugar starts to rise, the damage is often already well established.

HOMA-IR — which stands for Homeostatic Model Assessment of Insulin Resistance — is a simple, validated mathematical model that estimates the degree of insulin resistance from two routine fasting blood tests: fasting glucose and fasting insulin. It was developed in 1985 by Matthews and colleagues at the University of Oxford, and despite being nearly four decades old, it remains the most widely used method for assessing insulin resistance in both clinical practice and research settings worldwide — precisely because it requires nothing more than a standard blood draw and a simple calculation.

The logic behind HOMA-IR is straightforward. In a healthy individual with normal insulin sensitivity, the pancreas produces a modest amount of insulin to keep fasting blood sugar in the normal range. When insulin resistance develops, the pancreas has to produce progressively more insulin to achieve the same blood sugar control. A high fasting insulin level alongside a normal or mildly elevated fasting glucose is therefore the biochemical fingerprint of insulin resistance — and HOMA-IR captures this relationship in a single number. The higher the score, the greater the insulin resistance.

Formula Used

This calculator uses the original HOMA-IR formula developed by Matthews et al. in 1985, which remains the clinical and research standard:

For mg/dL users:

HOMA-IR = ( Fasting Glucose (mg/dL) × Fasting Insulin (µIU/mL) ) ÷ 405

For mmol/L users:

HOMA-IR = ( Fasting Glucose (mmol/L) × Fasting Insulin (µIU/mL) ) ÷ 22.5

Both expressions produce the same dimensionless HOMA-IR score — the only difference is the constant in the denominator, which accounts for the unit conversion between mg/dL and mmol/L. The constants 405 and 22.5 are derived from a normalization factor based on the expected insulin and glucose levels in a healthy, non-diabetic individual.

For example, a person with a fasting glucose of 95 mg/dL and a fasting insulin of 12 µIU/mL would have:

HOMA-IR = (95 × 12) ÷ 405 = 1140 ÷ 405 = 2.81

This result falls in the borderline range and would warrant further clinical evaluation alongside other metabolic markers.

It is worth noting that an updated version — HOMA2 — was developed by the same Oxford group using a more sophisticated computer model that accounts for variations in insulin secretion and hepatic glucose output more accurately than the original linear formula. HOMA2 is used primarily in research settings and requires specialized software. For routine clinical use and patient-facing calculators, the original HOMA-IR formula remains the standard and is what this calculator implements.

How to Use the Calculator?

1. 1. Get a fasting blood test — both glucose and insulin must be measured after at least 8 hours of fasting, from the same blood draw.
2. 2. Enter your fasting blood glucose value in mg/dL or mmol/L.
3. 3. Enter your fasting insulin value in µIU/mL (also written as mU/L — they are equivalent).
4. 4. Select your glucose unit — mg/dL or mmol/L.
5. 5. Click Calculate.
6. 6. Your HOMA-IR score and corresponding interpretation will be displayed.

Both values must come from the same fasting blood sample for the result to be valid. A glucose value from one day and an insulin value from another — or values taken after eating — will produce a meaningless HOMA-IR score. Fasting insulin in particular is highly sensitive to recent food intake and will be significantly elevated even hours after a meal, which is why strict fasting is non-negotiable for this test.

Understanding Your Results

HOMA-IR does not have a single universally agreed cutoff — reference ranges vary slightly between laboratories, ethnic populations, and research studies. The following thresholds are the most widely cited in clinical literature and represent a reasonable general reference for adults:

These thresholds are general population references. Some studies define insulin resistance at a HOMA-IR above 2.0, while others use cutoffs of 2.5 or 3.0 depending on the population studied. People of South Asian and East Asian descent tend to develop metabolic complications at lower HOMA-IR values than populations of European descent — meaning standard cutoffs may underestimate risk in these groups. Always interpret your result in the context of your full clinical picture and with guidance from your healthcare provider.

Clinical Significance

HOMA-IR fills a gap that standard blood tests leave open. Fasting glucose and HbA1c tell you what is happening to blood sugar — but they do not tell you why, or how hard the pancreas is working to maintain that control. HOMA-IR answers that question.

1. 1. Early detection of insulin resistance before blood sugar becomes abnormal is perhaps the most important clinical application of HOMA-IR. A person can have a fasting glucose of 90 mg/dL — perfectly normal by any standard — yet have a fasting insulin of 25 µIU/mL and a HOMA-IR of 5.6, indicating significant insulin resistance. Standard glucose testing would miss this entirely. HOMA-IR catches it years before diabetes develops, when lifestyle interventions are most effective and most likely to prevent progression.
2. 2. Metabolic syndrome assessment uses HOMA-IR as one of the most sensitive markers of the underlying insulin resistance that drives this cluster of conditions — central obesity, elevated triglycerides, low HDL cholesterol, hypertension, and impaired fasting glucose. Identifying insulin resistance early in metabolic syndrome allows treatment to target the root cause rather than each individual component separately.
3. 3. PCOS diagnosis and management relies heavily on HOMA-IR because insulin resistance is a central feature of polycystic ovary syndrome in the majority of affected women — regardless of body weight. Lean women with PCOS can have significant insulin resistance that standard screening would miss. HOMA-IR provides an objective measure that guides decisions about insulin-sensitizing treatments like metformin and inositol.
4. 4. Non-alcoholic fatty liver disease (NAFLD) and NASH are strongly driven by insulin resistance, and HOMA-IR is one of the most studied non-invasive markers for assessing its severity. A high HOMA-IR in a patient with elevated liver enzymes or hepatic steatosis on imaging supports insulin resistance as the primary driver and guides treatment accordingly.
5. 5. Cardiovascular risk stratification is enhanced by HOMA-IR beyond what traditional risk factors capture. Insulin resistance independently increases the risk of atherosclerosis, hypertension, and major cardiovascular events — and HOMA-IR quantifies this risk in a way that fasting glucose and lipid panels do not. Some cardiologists now include HOMA-IR as part of comprehensive cardiovascular risk assessment in high-risk patients.
6. 6. Treatment monitoring in patients with insulin resistance or prediabetes uses serial HOMA-IR measurements to track whether lifestyle interventions — dietary changes, exercise, weight loss — or pharmacological treatments like metformin are actually improving insulin sensitivity over time. A falling HOMA-IR score over months is objective evidence that the intervention is working at the metabolic level.
7. 7. Research and epidemiology use HOMA-IR more than almost any other insulin resistance metric precisely because it requires only two standard blood tests and a simple calculation — making it feasible to measure in large population studies where more complex techniques like the hyperinsulinemic-euglycemic clamp are not practical.

Limitations of HOMA-IR Calculator

HOMA-IR is the most practical tool available for routine insulin resistance assessment — but it comes with real limitations that are important to understand before drawing conclusions from your score.

1. 1. Fasting insulin measurement is not standardized. Unlike glucose, which is measured by highly consistent enzymatic methods across laboratories, insulin assays vary significantly between different laboratory platforms. The same blood sample can produce meaningfully different fasting insulin values depending on which assay is used — and because HOMA-IR is directly proportional to fasting insulin, this inter-assay variability translates directly into variability in the HOMA-IR score. Always interpret your result in the context of your specific laboratory's reference ranges.
2. 2. HOMA-IR is not reliable in people who do not produce their own insulin. In Type 1 diabetes and in advanced Type 2 diabetes where pancreatic beta cell function is severely impaired, fasting insulin levels reflect exogenous (injected) insulin rather than endogenous secretion — making the HOMA-IR model physiologically invalid in these patients. The formula was developed for people with intact or partially intact beta cell function.
3. 3. Single measurements are unreliable. Fasting insulin in particular is biologically variable from day to day — affected by recent dietary patterns, sleep quality, stress, physical activity in the preceding 24 to 48 hours, and even the timing of the blood draw within the morning. A single HOMA-IR score should never be interpreted in isolation. Serial measurements over time, or averaging across multiple measurements, give a far more reliable picture.
4. 4. Cutoff values are not universally agreed upon and vary between studies, ethnic populations, and clinical guidelines. A HOMA-IR of 2.5 that falls in the normal range by one study's criteria may indicate early insulin resistance by another's. This lack of standardization is a genuine limitation of the tool in clinical practice and means results must always be contextualized by a clinician familiar with local reference ranges and population-specific data.
5. 5. HOMA-IR does not distinguish between hepatic and peripheral insulin resistance. Insulin resistance can occur primarily in the liver — where insulin normally suppresses glucose production — or primarily in peripheral tissues like muscle and fat — where insulin normally promotes glucose uptake. These two forms of resistance have different clinical implications and require different interventions, but HOMA-IR cannot differentiate between them.
6. 6. It does not measure beta cell function directly. While HOMA-IR estimates insulin resistance, beta cell function — the pancreas's capacity to produce insulin — is a separate parameter that also declines in type 2 diabetes. A companion metric called HOMA-B (also derived from the same model) estimates beta cell function, and the two are often interpreted together in research settings for a more complete picture of glucose homeostasis.
7. 7. The gold standard for insulin resistance measurement — the hyperinsulinemic-euglycemic clamp — is far more accurate than HOMA-IR but requires specialized equipment, continuous intravenous infusions of insulin and glucose over several hours, and expert clinical supervision. It is used primarily in research. HOMA-IR is a practical compromise — not perfect, but widely validated and clinically useful when interpreted correctly.
8. 8. HOMA-IR should always be interpreted alongside:
   1. - Fasting glucose and HbA1c
   2. - Fasting lipid profile (triglycerides, HDL cholesterol)
   3. - Waist circumference and waist-to-hip ratio
   4. - Blood pressure
   5. - Liver function tests and liver ultrasound where indicated
   6. - Full clinical assessment by a qualified endocrinologist or metabolic physician

Disclaimer

This HOMA-IR calculator is for educational and informational purposes only and does not constitute medical advice or diagnosis.

The HOMA-IR score generated by this tool is a mathematical estimate based on fasting glucose and fasting insulin values you enter. It is not a clinical diagnosis of insulin resistance, prediabetes, or any other condition. Reference ranges vary between laboratories, ethnic populations, and clinical guidelines — and a single score should never be interpreted without the full clinical context that a qualified healthcare provider would consider.

If your result falls in the borderline or elevated range, we encourage you to share it with your doctor rather than drawing conclusions independently. Do not make changes to your diet, medications, or lifestyle based solely on this result without professional guidance.

We do not store or share any data you enter. The creators of this tool accept no liability for decisions made based on its output.